Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | ACR | P10323 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223804 | 0.93 | GAA (0.49) | MAPTGAAKMT2AALDH1A1LMNA | |
| SCHEMBL429811 | 0.89 | GAA (0.52) | MAPTGAAKMT2AALDH1A1LMNA | |
| SCHEMBL431493 | 0.86 | GAA (0.56) | MAPTGAAKMT2AALDH1A1LMNA | |
| SCHEMBL28446011 | 0.85 | KMT2A (0.50) | MAPTGAAKMT2AALDH1A1LMNA | |
| SCHEMBL220612 | 0.81 | MAPT (0.38) | MAPTGAAKMT2ANR1H4ALDH1A1 | |
| SCHEMBL11705905 | 0.81 | GAA (0.51) | MAPTGAAKMT2AALDH1A1LMNA | |
| SCHEMBL2612507 | 0.80 | MAPT (0.43) | MAPTGAAKMT2ANR1H4PRSS1 | |
| SCHEMBL2612505 | 0.80 | MAPT (0.43) | MAPTGAAKMT2ANR1H4PRSS1 | |
| SCHEMBL27941396 | 0.80 | GAA (0.52) | GAAKMT2AALDH1A1LMNAAGTR1 | |
| SCHEMBL2252361 | 0.79 | GAA (0.57) | MAPTGAAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349210-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120003401-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003401-A1 | MESOGENIC STABILIZERS | PYM1, BMI1, C1S | MAPT 1853/4885GAA 4810/4885KMT2A 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.